Combination of AD5-10 and epirubicin in treating rheumatoid arthritis.
- Author:
Jian-suo ZHOU
1
;
Juan SHI
;
Jie-qing ZHU
;
Hai-qin YUAN
;
Yan-xin LIU
;
Xin YOU
;
De-xian ZHENG
Author Information
- Publication Type:Journal Article
- MeSH: Antibodies, Monoclonal; pharmacology; Apoptosis; drug effects; Apoptosis Regulatory Proteins; metabolism; Arthritis, Rheumatoid; drug therapy; metabolism; pathology; Cells, Cultured; Epirubicin; pharmacology; Humans; Receptors, TNF-Related Apoptosis-Inducing Ligand; immunology; Synovial Membrane; cytology; drug effects; metabolism
- From: Acta Academiae Medicinae Sinicae 2011;33(4):367-370
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the mechanism of anti-death receptor 5-10 (AD5-10) combined with epirubicin in treating rheumatoid arthritis (RA).
METHODSWe detected the cell viability of the fibroblast-like synoviocytes (FLS) from RA patients with MTT. The expression level of apoptosis signaling pathways protein, p53, and p21 were evaluated with Western blot.
RESULTSWe found that epirubicin, at different doses, could enhance the effect of AD5-10 on FLS, promoting the apoptosis of FLS. The expression levels of caspase-3, -8, -9, c-FLIP, Bcl-2, p53, and p21 in the FLS changed after epirubicin treatment.
CONCLUSIONEpirubicin may coordinate with AD5-10 in inducing FLS apoptosis through affecting the levels of p53, p21, c-FLIP, and Bcl-2.
